- Home
- MYSE vs LSTA Comparison
MYSE vs LSTA Comparison
Compare MYSE & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYSE | LSTA |
|---|---|---|
| Founded | 2014 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Misc Health and Biotechnology Services |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 15.9M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MYSE | LSTA |
|---|---|---|
| Price | $1.37 | $1.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.9K | ★ 89.7K |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.64 | 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | $550.00 | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 26.15 | ★ 56.90 |
| 52 Week Low | $1.37 | $0.96 |
| 52 Week High | $11.54 | $5.07 |
Technical Indicators
Market Signals| Indicator | MYSE | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 38.80 |
| Support Level | N/A | $0.97 |
| Resistance Level | $3.61 | $1.28 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 10.46 | 29.10 |
Price Performance
Historical ComparisonAbout MYSE Myseum Inc.
Myseum.AI Inc is an integrate proprietary privacy-first artificial intelligence (AI) and social media technology company. The Company is developing privacy-first agentic localized AI agents to assist in managing personal media such as photos, videos and messages, while maintaining privacy.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.